ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 0013 • ACR Convergence 2023

    A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients

    Mehreen Elahee1, Kathryne Marks2, Ifeoluwakiisi Adejoorin2, Lin Chen2, Derrick Todd2, Jonathan Coblyn2, Elena Massarotti2, Susan Ritter2, Michael Weinblatt3, Daniel Solomon4 and Deepak Rao2, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Brigham and Women's Hospital, Boston, MA, 3Harvard Medical School, Waban, MA, 4Brigham and Women's Hospital, Newton, MA

    Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
  • Abstract Number: 0739 • ACR Convergence 2023

    Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis

    Sali Merjanah1, Devin Driscoll2, Christine Peloquin3, Jean liew3 and Maureen Dubreuil4, 1Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2Boston University/Boston Medical Center, Boston, MA, 3Boston University, Boston, MA, 4Department of Rheumatology, Boston University School of Medicine, Milton, MA

    Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…
  • Abstract Number: 1439 • ACR Convergence 2023

    Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA

    Jakub Zavada1, Jana Baranová2, Karel Pavelka3, Jiri Vencovsky4, Pavel Horak5, Lenka Klementová6 and Ladislav Senolt7, 1Institute of Rheumatology; Charles University, Prague, Czech Republic, 2Institute of Biostatistics and Analyses, Brno, Czech Republic, 3Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 4Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic, 6Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic, 7Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: To compare drug survival, effectiveness and safety of anti-IL17A with anti-TNF drugs as first line biologic therapy in patients (pts) with PsA using real…
  • Abstract Number: 2251 • ACR Convergence 2023

    Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study

    Peter C. Taylor1, David Walsh2, Tsutomu Takeuchi3, Bruno Fautrel4, Janet Pope5, Koji Kato6, Arathi Setty6, Tianming Gao6, Diane Caballero7, Ralph Lippe8 and Arthur Kavanaugh9, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Sorbonne Université APHP, Paris, France, 5University of Western Ontario, London, ON, Canada, 6AbbVie, Inc., North Chicago, IL, 7AbbVie, Inc., Chicago, IL, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 9University of California San Diego, School of Medicine, Riverside, CA

    Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…
  • Abstract Number: 0072 • ACR Convergence 2023

    Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons

    Marie Naingeon1, Samuel Bitoun2, Matthieu roulleaux Dugage1, Caroline de Oliveira1, Caroline Berthot1, Xavier Mariette3, Nathalie Chaput1 and Gaetane Nocturne4, 1LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, 2CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, 3Université Paris-Saclay, Le Kremlin-Bicêtre, France, 4APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…
  • Abstract Number: 0775 • ACR Convergence 2023

    Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study

    Amy Peeters, C.A.J Michielsens, Elien Mahler, Lise Verhoef, Alfons den Broeder, Nathan den Broeder and Noortje van Herwaarden, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…
  • Abstract Number: 1557 • ACR Convergence 2023

    De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

    Sinem Nihal Esatoglu1, Ozge Sonmez2, Didar Ucar3, Elif Kaymaz4, Yesim Ozguler5, Serdal Ugurlu6, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko7, Vedat Hamuryudan1, Ugur Uygunoglu8, Zekayi Kutlubay9 and Gulen Hatemi1, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Istanbul, Turkey, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 8Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet's syndrome…
  • Abstract Number: 2474 • ACR Convergence 2023

    Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience

    Ilaria Maccora1, Valerio Accardo2, Marco Cattalini3, ilaria Pagnini4, Andrea Taddio5, Edoardo Marrani6, francesco La Torre7, Matteo Trevisan8, Maria Vincenza Mastrolia9 and Gabriele Simonini10, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2University of Florence, Florence, Italy, 3Spedali Civili di Brescia, Brescia, Italy, 4Meyer Children's Hospital IRCCS, Florence, Italy, 5Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, 6University of Florence, Firenze, Italy, 7Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, 8IRCCS Burlo Garofalo, Trieste, Italy, 9NEUROFARBA Department, University of Florence, Florence, Italy, 10Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy

    Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
  • Abstract Number: 0264 • ACR Convergence 2023

    A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis

    Marcia Genta1 and Allison DiPasquale2, 1Dallas Arthritis Center, Dallas, TX, 2Texas Oncology - Medical City Dallas, Dallas, TX

    Background/Purpose: Idiopathic Granulomatous Mastitis (IGM) is a rare often self-limited chronic inflammatory breast disease of unknown etiology characterized by non-caseating granulomas in breast tissue, affecting…
  • Abstract Number: 0779 • ACR Convergence 2023

    Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)

    Laura PINA VEGAS1, Laetitia Penso2, Emilie Sbidian3 and pascal claudepierre4, 1Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France, 2Université Paris Est Créteil, Créteil, France, 3Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, 4Universitary Henri Mondor Hospital, Creteil, France

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…
  • Abstract Number: 1559 • ACR Convergence 2023

    Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

    Nuria Barroso-Garcia1, Jose Luis Martin-Varillas2, Lara Sanchez-Bilbao3, Ivan Ferraz Amaro4, Vanesa Calvo Río5, Alfredo Adán6, Inés Hernanz-Rodriguez7, Emma Beltran-Catalan8, David Diaz-Valle9, Marisa Hernandez-Garfella10, Lucia Martinez-Costa11, Manuel Diaz-Llopis12, Jose M Herreras13, Olga Maiz-Alonso14, Ignacio Torre-Salaberri15, Antonio Atanes Sandoval16, Santos Insua-Vilariño17, Raquel Almodovar18, Patricia Fanlo-Mateo19, Juan Ramon De Dios20, Angel Garcia-Aparicio21, Sergio rodriguez-Montero22, Vega Jovani23, Patricia Moya24, Eva Peña Sainz-Pardo25, Jose Luis Hernandez26 and Ricardo Blanco27, 1Hospital Universitario Puerta del Mar, Cadiz, Spain, 2Hospital de Laredo, Laredo, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Valdecilla Hospital, Santander, Spain, 6Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 8HOSPITAL DEL MAR, Barcelona, Spain, 9Hospital Clinico San Carlos, Madrid, Spain, 10Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, 11Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, 12Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, 13Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 14University Hospital Donostia, San Sebastian, Spain, 15Hospital Universitario de Basurto, Bilbao, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 17Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, 18Alcorcón Foundation University Hospital, Madrid, Spain, 19Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 20Osakidetza, Vitoria, Spain, 21Hospital Universitario de Toledo, Toledo, Spain, 22Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 24Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 25Pediatric, Hospital 12 de Octubre, Madrid, Spain, 26Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 27Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
  • Abstract Number: 2512 • ACR Convergence 2023

    Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis

    Jacques-Eric Gottenberg1, Nathanaël Sedmak2, Pierre Tran Ba Loc2, Thibaut Fabacher2, Thibaut Bahougne2, Cécile Arnold2, Guillaume Desjeux3, Hervé Servy4, Nicolas Meyer2, Erik Sauleau2, Raphaele Seror5 and Eden Sebbag6, 1Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 2Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 3e-Health Services Sanoia, Gemenos, France, 4e-Health Services Sanoia, La Ciotat, France, 5University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 6Université de Strasbourg, Strasbourg, France

    Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…
  • Abstract Number: 0359 • ACR Convergence 2023

    Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment

    Chelsea Vallejos1, Jennifer Cooper2 and Ingrid Pan1, 1Children's Hospital Colorado, Aurora, CO, 2University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…
  • Abstract Number: 0805 • ACR Convergence 2023

    De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis

    Jiha Lee1, Navasuja Kumar1, Mohammed Kabeto1, Andrzej Galecki1, Chiang-Hua Chang1, Namrata Singh2, Raymond Yung3, Una Makris4 and Julie Bynum1, 1University of Michigan, Ann Arbor, MI, 2University of Washington, Bellevue, WA, 3Michigan Medicine, Ann Arbor, MI, 4UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Biologic disease modifying anti-rheumatic drugs (bDMARDs) such as anti-tumor necrosis factors(anti-TNFs) improve clinical and radiographic outcomes in rheumatoid arthritis (RA). However, their use is…
  • Abstract Number: 1582 • ACR Convergence 2023

    Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

    Bryant England1, Joshua Baker2, Michael George2, Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Harlan Sayles1, Fang Yu1, Jorge Rojas Jr3, Brian Sauer4, Grant Cannon5, Jeffrey R Curtis6 and Ted R Mikuls7, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Puget Sound VA and University of Utah, Seattle, WA, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology